Vaccine-elicited receptor-binding site antibodies neutralize two New World hemorrhagic fever arenaviruses
- Autores
- Clark, Lars E; Mahmutovic, Selma; Raymond, Donald D; Dilanyan, Taleen; Koma, Takaaki; Manning, John T; Shankar, Sundaresh; Levis, Silvana; Briggiler, Ana M.; Enria, Delia; Wucherpfennig, Kai W; Paessler, Slobodan; Abraham, Jonathan
- Año de publicación
- 2018
- Idioma
- inglés
- Tipo de recurso
- artículo
- Estado
- versión publicada
- Descripción
- Fil: Clark, Lars E. Department of Microbiology and Immunobiology, Harvard Medical School, Boston; Estados Unidos.
Fil: Mahmutovic, Selma. Laboratory of Molecular Medicine, Boston Children's Hospital, Harvard Medical School, Boston; Estados Unidos.
Fil: Raymond, Donald D. Laboratory of Molecular Medicine, Boston Children's Hospital, Harvard Medical School, Boston; Estados Unidos.
Fil: Dilanyan, Taleen. Department of Microbiology and Immunobiology, Harvard Medical School, Boston; Estados Unidos.
Fil: Koma, Takaaki. Department of Pathology, University of Texas Medical Branch at Galveston, Galveston; Estados Unidos.
Fil: Manning, John T. Department of Pathology, University of Texas Medical Branch at Galveston, Galveston; Estados Unidos.
Fil: Shankar, Sundaresh. Department of Microbiology and Immunobiology, Harvard Medical School, Boston; Estados Unidos.
Fil: Levis, Silvana C. ANLIS Dr.C.G.Malbrán. Instituto Nacional de Enfermedades Virales Humanas; Argentina.
Fil: Briggiler, Ana M. ANLIS Dr.C.G.Malbrán. Instituto Nacional de Enfermedades Virales Humanas; Argentina.
Fil: Enria, Delia A. ANLIS Dr.C.G.Malbrán. Instituto Nacional de Enfermedades Virales Humanas; Argentina.
Fil: Wucherpfennig, Kai W. Laboratory of Molecular Medicine, Boston Children's Hospital, Harvard Medical School, Boston; Estados Unidos.
Fil: Paessler, Slobodan. Department of Pathology, University of Texas Medical Branch at Galveston, Galveston; Estados Unidos.
Fil: Abraham, Jonathan. Department of Microbiology and Immunobiology, Harvard Medical School, Boston; Estados Unidos.
While five arenaviruses cause human hemorrhagic fevers in the Western Hemisphere, only Junin virus (JUNV) has a vaccine. The GP1 subunit of their envelope glycoprotein binds transferrin receptor 1 (TfR1) using a surface that substantially varies in sequence among the viruses. As such, receptor-mimicking antibodies described to date are type-specific and lack the usual breadth associated with this mode of neutralization. Here we isolate, from the blood of a recipient of the live attenuated JUNV vaccine, two antibodies that cross-neutralize Machupo virus with varying efficiency. Structures of GP1-Fab complexes explain the basis for efficient cross-neutralization, which involves avoiding receptor mimicry and targeting a conserved epitope within the receptor-binding site (RBS). The viral RBS, despite its extensive sequence diversity, is therefore a target for cross-reactive antibodies with activity against New World arenaviruses of public health concern. - Fuente
- Nature Communications 2018 ;9(1):1884.
- Materia
-
Arenavirus
Fiebre Hemorrágica Americana - Nivel de accesibilidad
- acceso abierto
- Condiciones de uso
- Repositorio
- Institución
- Administración Nacional de Laboratorios e Institutos de Salud "Dr. Carlos G. Malbrán"
- OAI Identificador
- oai:sgc.anlis.gob.ar:Publications/123456789/2131
Ver los metadatos del registro completo
id |
SGCANLIS_c14b6882e84566657ede55a377b410e5 |
---|---|
oai_identifier_str |
oai:sgc.anlis.gob.ar:Publications/123456789/2131 |
network_acronym_str |
SGCANLIS |
repository_id_str |
a |
network_name_str |
Sistema de Gestión del Conocimiento ANLIS MALBRÁN |
spelling |
Vaccine-elicited receptor-binding site antibodies neutralize two New World hemorrhagic fever arenavirusesClark, Lars EMahmutovic, SelmaRaymond, Donald DDilanyan, TaleenKoma, TakaakiManning, John TShankar, SundareshLevis, SilvanaBriggiler, Ana M.Enria, DeliaWucherpfennig, Kai WPaessler, SlobodanAbraham, JonathanArenavirusFiebre Hemorrágica AmericanaFil: Clark, Lars E. Department of Microbiology and Immunobiology, Harvard Medical School, Boston; Estados Unidos.Fil: Mahmutovic, Selma. Laboratory of Molecular Medicine, Boston Children's Hospital, Harvard Medical School, Boston; Estados Unidos.Fil: Raymond, Donald D. Laboratory of Molecular Medicine, Boston Children's Hospital, Harvard Medical School, Boston; Estados Unidos.Fil: Dilanyan, Taleen. Department of Microbiology and Immunobiology, Harvard Medical School, Boston; Estados Unidos.Fil: Koma, Takaaki. Department of Pathology, University of Texas Medical Branch at Galveston, Galveston; Estados Unidos.Fil: Manning, John T. Department of Pathology, University of Texas Medical Branch at Galveston, Galveston; Estados Unidos.Fil: Shankar, Sundaresh. Department of Microbiology and Immunobiology, Harvard Medical School, Boston; Estados Unidos.Fil: Levis, Silvana C. ANLIS Dr.C.G.Malbrán. Instituto Nacional de Enfermedades Virales Humanas; Argentina.Fil: Briggiler, Ana M. ANLIS Dr.C.G.Malbrán. Instituto Nacional de Enfermedades Virales Humanas; Argentina.Fil: Enria, Delia A. ANLIS Dr.C.G.Malbrán. Instituto Nacional de Enfermedades Virales Humanas; Argentina.Fil: Wucherpfennig, Kai W. Laboratory of Molecular Medicine, Boston Children's Hospital, Harvard Medical School, Boston; Estados Unidos.Fil: Paessler, Slobodan. Department of Pathology, University of Texas Medical Branch at Galveston, Galveston; Estados Unidos.Fil: Abraham, Jonathan. Department of Microbiology and Immunobiology, Harvard Medical School, Boston; Estados Unidos.While five arenaviruses cause human hemorrhagic fevers in the Western Hemisphere, only Junin virus (JUNV) has a vaccine. The GP1 subunit of their envelope glycoprotein binds transferrin receptor 1 (TfR1) using a surface that substantially varies in sequence among the viruses. As such, receptor-mimicking antibodies described to date are type-specific and lack the usual breadth associated with this mode of neutralization. Here we isolate, from the blood of a recipient of the live attenuated JUNV vaccine, two antibodies that cross-neutralize Machupo virus with varying efficiency. Structures of GP1-Fab complexes explain the basis for efficient cross-neutralization, which involves avoiding receptor mimicry and targeting a conserved epitope within the receptor-binding site (RBS). The viral RBS, despite its extensive sequence diversity, is therefore a target for cross-reactive antibodies with activity against New World arenaviruses of public health concern.Yes2018-05info:ar-repo/semantics/articuloinfo:eu-repo/semantics/articleinfo:eu-repo/semantics/publishedVersionapplication/pdf2041-1723http://sgc.anlis.gob.ar/handle/123456789/213110.1038/s41467-018-04271-zNature Communications 2018 ;9(1):1884.reponame:Sistema de Gestión del Conocimiento ANLIS MALBRÁNinstname:Administración Nacional de Laboratorios e Institutos de Salud "Dr. Carlos G. Malbrán"instacron:ANLISNature communicationsenginfo:eu-repo/semantics/openAccess2025-09-29T14:30:39Zoai:sgc.anlis.gob.ar:Publications/123456789/2131Institucionalhttp://sgc.anlis.gob.ar/Organismo científico-tecnológicoNo correspondehttp://sgc.anlis.gob.ar/oai/biblioteca@anlis.gov.arArgentinaNo correspondeNo correspondeNo correspondeopendoar:a2025-09-29 14:30:40.061Sistema de Gestión del Conocimiento ANLIS MALBRÁN - Administración Nacional de Laboratorios e Institutos de Salud "Dr. Carlos G. Malbrán"false |
dc.title.none.fl_str_mv |
Vaccine-elicited receptor-binding site antibodies neutralize two New World hemorrhagic fever arenaviruses |
title |
Vaccine-elicited receptor-binding site antibodies neutralize two New World hemorrhagic fever arenaviruses |
spellingShingle |
Vaccine-elicited receptor-binding site antibodies neutralize two New World hemorrhagic fever arenaviruses Clark, Lars E Arenavirus Fiebre Hemorrágica Americana |
title_short |
Vaccine-elicited receptor-binding site antibodies neutralize two New World hemorrhagic fever arenaviruses |
title_full |
Vaccine-elicited receptor-binding site antibodies neutralize two New World hemorrhagic fever arenaviruses |
title_fullStr |
Vaccine-elicited receptor-binding site antibodies neutralize two New World hemorrhagic fever arenaviruses |
title_full_unstemmed |
Vaccine-elicited receptor-binding site antibodies neutralize two New World hemorrhagic fever arenaviruses |
title_sort |
Vaccine-elicited receptor-binding site antibodies neutralize two New World hemorrhagic fever arenaviruses |
dc.creator.none.fl_str_mv |
Clark, Lars E Mahmutovic, Selma Raymond, Donald D Dilanyan, Taleen Koma, Takaaki Manning, John T Shankar, Sundaresh Levis, Silvana Briggiler, Ana M. Enria, Delia Wucherpfennig, Kai W Paessler, Slobodan Abraham, Jonathan |
author |
Clark, Lars E |
author_facet |
Clark, Lars E Mahmutovic, Selma Raymond, Donald D Dilanyan, Taleen Koma, Takaaki Manning, John T Shankar, Sundaresh Levis, Silvana Briggiler, Ana M. Enria, Delia Wucherpfennig, Kai W Paessler, Slobodan Abraham, Jonathan |
author_role |
author |
author2 |
Mahmutovic, Selma Raymond, Donald D Dilanyan, Taleen Koma, Takaaki Manning, John T Shankar, Sundaresh Levis, Silvana Briggiler, Ana M. Enria, Delia Wucherpfennig, Kai W Paessler, Slobodan Abraham, Jonathan |
author2_role |
author author author author author author author author author author author author |
dc.subject.none.fl_str_mv |
Arenavirus Fiebre Hemorrágica Americana |
topic |
Arenavirus Fiebre Hemorrágica Americana |
dc.description.none.fl_txt_mv |
Fil: Clark, Lars E. Department of Microbiology and Immunobiology, Harvard Medical School, Boston; Estados Unidos. Fil: Mahmutovic, Selma. Laboratory of Molecular Medicine, Boston Children's Hospital, Harvard Medical School, Boston; Estados Unidos. Fil: Raymond, Donald D. Laboratory of Molecular Medicine, Boston Children's Hospital, Harvard Medical School, Boston; Estados Unidos. Fil: Dilanyan, Taleen. Department of Microbiology and Immunobiology, Harvard Medical School, Boston; Estados Unidos. Fil: Koma, Takaaki. Department of Pathology, University of Texas Medical Branch at Galveston, Galveston; Estados Unidos. Fil: Manning, John T. Department of Pathology, University of Texas Medical Branch at Galveston, Galveston; Estados Unidos. Fil: Shankar, Sundaresh. Department of Microbiology and Immunobiology, Harvard Medical School, Boston; Estados Unidos. Fil: Levis, Silvana C. ANLIS Dr.C.G.Malbrán. Instituto Nacional de Enfermedades Virales Humanas; Argentina. Fil: Briggiler, Ana M. ANLIS Dr.C.G.Malbrán. Instituto Nacional de Enfermedades Virales Humanas; Argentina. Fil: Enria, Delia A. ANLIS Dr.C.G.Malbrán. Instituto Nacional de Enfermedades Virales Humanas; Argentina. Fil: Wucherpfennig, Kai W. Laboratory of Molecular Medicine, Boston Children's Hospital, Harvard Medical School, Boston; Estados Unidos. Fil: Paessler, Slobodan. Department of Pathology, University of Texas Medical Branch at Galveston, Galveston; Estados Unidos. Fil: Abraham, Jonathan. Department of Microbiology and Immunobiology, Harvard Medical School, Boston; Estados Unidos. While five arenaviruses cause human hemorrhagic fevers in the Western Hemisphere, only Junin virus (JUNV) has a vaccine. The GP1 subunit of their envelope glycoprotein binds transferrin receptor 1 (TfR1) using a surface that substantially varies in sequence among the viruses. As such, receptor-mimicking antibodies described to date are type-specific and lack the usual breadth associated with this mode of neutralization. Here we isolate, from the blood of a recipient of the live attenuated JUNV vaccine, two antibodies that cross-neutralize Machupo virus with varying efficiency. Structures of GP1-Fab complexes explain the basis for efficient cross-neutralization, which involves avoiding receptor mimicry and targeting a conserved epitope within the receptor-binding site (RBS). The viral RBS, despite its extensive sequence diversity, is therefore a target for cross-reactive antibodies with activity against New World arenaviruses of public health concern. |
description |
Fil: Clark, Lars E. Department of Microbiology and Immunobiology, Harvard Medical School, Boston; Estados Unidos. |
publishDate |
2018 |
dc.date.none.fl_str_mv |
2018-05 |
dc.type.none.fl_str_mv |
info:ar-repo/semantics/articulo info:eu-repo/semantics/article info:eu-repo/semantics/publishedVersion |
format |
article |
status_str |
publishedVersion |
dc.identifier.none.fl_str_mv |
2041-1723 http://sgc.anlis.gob.ar/handle/123456789/2131 10.1038/s41467-018-04271-z |
identifier_str_mv |
2041-1723 10.1038/s41467-018-04271-z |
url |
http://sgc.anlis.gob.ar/handle/123456789/2131 |
dc.language.none.fl_str_mv |
eng |
language |
eng |
dc.relation.none.fl_str_mv |
Nature communications |
dc.rights.none.fl_str_mv |
info:eu-repo/semantics/openAccess |
eu_rights_str_mv |
openAccess |
dc.format.none.fl_str_mv |
application/pdf |
dc.publisher.none.fl_str_mv |
Yes |
publisher.none.fl_str_mv |
Yes |
dc.source.none.fl_str_mv |
Nature Communications 2018 ;9(1):1884. reponame:Sistema de Gestión del Conocimiento ANLIS MALBRÁN instname:Administración Nacional de Laboratorios e Institutos de Salud "Dr. Carlos G. Malbrán" instacron:ANLIS |
reponame_str |
Sistema de Gestión del Conocimiento ANLIS MALBRÁN |
collection |
Sistema de Gestión del Conocimiento ANLIS MALBRÁN |
instname_str |
Administración Nacional de Laboratorios e Institutos de Salud "Dr. Carlos G. Malbrán" |
instacron_str |
ANLIS |
institution |
ANLIS |
repository.name.fl_str_mv |
Sistema de Gestión del Conocimiento ANLIS MALBRÁN - Administración Nacional de Laboratorios e Institutos de Salud "Dr. Carlos G. Malbrán" |
repository.mail.fl_str_mv |
biblioteca@anlis.gov.ar |
_version_ |
1844621859155345408 |
score |
12.559606 |